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Aneuploidy is a major cause of perinatal death and 
childhood handicap.[1] Improved methods of screening 
for aneuploidy such as the nuchal translucency (NT) 
scan, first- and second-trimester serum biochemistry 
and assessment of fetal anatomy and markers by 
ultrasound at 18 - 22 weeks’ gestation have replaced maternal age, which 
is known to be a poor method of screening. With improved screening 
methods, there is a need for diagnostic tests such as a chorionic villous 
sample and amniocentesis to confirm or exclude aneuploidy. These 
invasive tests are associated with a risk of miscarriage, and should 
therefore only be carried out in high-risk pregnancies.
HIV and birth defects
The situation is complicated further if a woman at high risk for 
aneuploidy is also HIV-positive. Knowledge of the risks of HIV 
transmission to the fetus from invasive procedures is important to 
ensure adequate counselling and management.
More than half of the estimated 33 million people in South 
Africa (SA) living with HIV/AIDS are women, and most are of 
childbearing age.[2] The SA Department of Health study estimates 
that in 2011, 29.5% of pregnant women were HIV-positive. KwaZulu-
Natal recorded the highest HIV prevalence of 37.4%, while the 
Northern Cape recorded the lowest at 17%.[3] The use of highly active 
antiretroviral therapy (HAART) has led to a significant reduction in 
morbidity and mortality from HIV infection and a decline in mother-
to-child transmission (MTCT).
Globally, birth defects occur in approximately 2 - 3% of live 
births, although minor anomalies are more frequent.[4] The birth 
prevalence of serious defects is lower in industrialised countries than 
in developing countries. An HIV-positive woman is not at increased 
risk of having a child with a birth defect compared with the average 
population, even if she is on antiretroviral therapy (ART).[5,6]
HIV and amniocentesis
There is limited literature on the known risk of HIV transmission 
during amniocentesis. Before HAART, invasive procedures such 
as amniocentesis were avoided owing to the increased risk of 
MTCT.[7-12] Recent literature suggests that it is safe to perform amnio-
centesis in women on HAART with suppressed viral loads (preferably 
undetectable) and when transplacental passage of the needle is 
avoided.[7,10-15]
HIV counselling and testing at the booking antenatal visit is routine, 
and many patients will only discover their HIV status during the 
pregnancy. Unfortunately, in SA many women initiate antenatal care 
late in pregnancy – in a recent study of over 27 000 pregnancies in the 
Peninsula Maternity and Neonatal Service in the Western Cape, 62% of 
women booked after 20 weeks[16] – thus missing the opportunity for first-
trimester screening. All women, regardless of whether they have had 
first-trimester screening, will ideally be offered a fetal abnormality scan 
between 18 and 22 weeks if resources are available. If a fetal abnormality 
is detected and amniocentesis is offered, there is often insufficient time 
to attain an undetectable viral load within the pre-viability period (i.e. 
before the generally accepted cut-off period of 24 weeks).
Groote Schuur Hospital (GSH) 
experience
At GSH, Cape Town, we undertook a survey of a case series of 27 
HIV-positive women who attended our genetics clinic over a 3-year 
period and accepted amniocentesis on the basis of screening tests 
that showed them to be at high risk. A total of 642 amniocenteses 
were undertaken over the period. Four per cent of these were in 
HIV-positive women, a small proportion because many HIV-positive 
patients declined amniocentesis after counselling and learning of the 
possible HIV transmission risk. The duration of HAART prior to 
amniocentesis, outcomes and postnatal care were recorded. In this 
group of 27 women, there were 6 pregnancy losses, 1 early neonatal 
death, 3 chromosomal abnormalities and 10 structural abnormalities. 
Although there were no cases of vertical HIV transmission in the 21 
liveborns, the number of patients was small and the duration of ART 
prior to amniocentesis varied widely from no treatment in 3 patients 
to more than 3 years of HAART in 4. Eighteen out of 21 patients had 
at least 10 days of HAART.
Discussion
All women should be able to opt for prenatal screening and 
diag nosis, and for amniocentesis if required, regardless of their 
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HIV status. It is a challenge to counsel patients about the risk of 
abnormality in their unborn child. In addition to this challenge, 
the risk of miscarriage and possible risk of HIV transmission 
associated with amniocentesis needs to be discussed in women who 
test positive for HIV.
We know that the overall risk of HIV transmission when 
amniocentesis is performed in early pregnancy is very low, and the 
addition of HAART reduces this risk significantly. It is reasonable 
to deduce that the longer the patient has been on HAART prior to 
amniocentesis, the lower the chance of HIV transmission. However, 
it is unclear what the minimum duration of treatment should be, 
and very large numbers of patients would be required to deduce the 
potential transmission rate with any reliability. While it is recognised 
that one of the biggest limitations in all studies is the absence of a 
control group, it would be unethical to do randomised controlled 
trials in this setting.
As clinicians, we have a responsibility to the mother to offer care 
that is standardised and does not discriminate in the presence of 
HIV infection. However, we also have a responsibility to the fetus 
and should not be exposing that fetus to an unnecessary risk of HIV 
transmission.
As with any diagnostic test, there should be a strong indication 
to do invasive testing, and this should only be offered when the risk 
of an abnormality is high. The risk of miscarriage and possible HIV 
transmission in HIV-positive women undergoing amniocentesis 
needs to be weighed against the benefits of a prenatal diagnosis, all of 
which needs to be communicated clearly to the patient so that she can 
make an informed decision. For some patients, having a child with 
a disability is not an option, and the benefit of a prenatal diagnosis 
outweighs the risks associated with amniocentesis. Conversely, 
amniocentesis should probably be avoided in patients who would not 
accept termination of pregnancy if the karyotype is abnormal.
Recommendations for management
If an HIV-positive patient accepts amniocentesis after counselling 
and consideration of the risks, HAART should be initiated and the 
procedure delayed until the viral load is undetectable. If there is not 
enough time to attain an undetectable viral load, it is reasonable 
for the patient to be on HAART for as long as possible prior to 
amniocentesis, as long as she understands the possible risks. 
The nature of the fetal abnormality may influence the decision 
to proceed with amniocentesis even when the viral load is not 
suppressed. If the abnormality is severe and will be associated 
with significant morbidity, exposing the fetus to a very low risk of 
HIV transmission will be outweighed by the benefit of a prenatal 
diagnosis.
Although not available in the state sector, and to many private 
patients because of the cost, it is worth noting that there is the 
option of having a non-invasive prenatal screening test (e.g. the 
Harmony test, which analyses cell-free DNA in the maternal blood 
and will identify 99% of fetuses with trisomy 21, 97% of fetuses 
with trisomy 18 and 92% of fetuses with trisomy 13).[17] This highly 
effective screening test does not carry the risk of miscarriage and 
HIV transmission. However, it does not identify other chromosomal 
abnormalities, and the high cost makes it inaccessible to many 
patients.
Summary
• There must be a strong indication to offer invasive testing. More 
effective screening methods such as an NT scan and a detailed 
fetal ultrasound scan looking for markers and defects must replace 
maternal age, which we know to be a poor method of screening.
• All women who have been offered and accept invasive testing must 
have an HIV test as part of their routine work-up.
• It is probably safe to perform amniocentesis in HIV-positive 
women on HAART, as long as their viral load is low (preferably 
undetectable) and transplacental passage of the needle is avoided.
• It may not be possible to wait for the viral load to become 
undetectable, and in carefully selected cases amniocentesis may be 
performed when the viral load is not suppressed.
• The risks of the amniocentesis must always be weighed against the 
benefit of a prenatal diagnosis.
• Amniocentesis should not be performed on HIV-positive women 
who are not on HAART.
• Careful consideration should be given to the patient who would 
not terminate the pregnancy if the karyotype is abnormal. In this 
case, invasive testing should preferably be avoided.
• Third-trimester amniocentesis, chorionic villous sampling and 
cordocentesis are not recommended in HIV-positive women.
• Consider a non-invasive – though costly – prenatal screening test.
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